Tempest Therapeutics Inc
TPST3.120USD
+0.140+4.70%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
13.85MMarket Cap
LossP/E TTM
More Details of Tempest Therapeutics Inc Company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Tempest Therapeutics Inc Info
Ticker SymbolTPST
Company nameTempest Therapeutics Inc
IPO dateOct 04, 2012
CEO- -
Number of employees24
Security typeOrdinary Share
Fiscal year-endOct 04
Address2000 Sierra Point Parkway
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone14157988589
Websitehttps://www.tempesttx.com/
Ticker SymbolTPST
IPO dateOct 04, 2012
CEO- -
Company Executives of Tempest Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Versant Ventures
5.48%
The Vanguard Group, Inc.
3.30%
Geode Capital Management, L.L.C.
0.83%
BlackRock Institutional Trust Company, N.A.
0.79%
Fidelity Management & Research Company LLC
0.67%
Other
88.93%
Shareholders
Shareholders
Proportion
Versant Ventures
5.48%
The Vanguard Group, Inc.
3.30%
Geode Capital Management, L.L.C.
0.83%
BlackRock Institutional Trust Company, N.A.
0.79%
Fidelity Management & Research Company LLC
0.67%
Other
88.93%
Shareholder Types
Shareholders
Proportion
Venture Capital
5.48%
Investment Advisor
5.46%
Investment Advisor/Hedge Fund
0.87%
Research Firm
0.12%
Individual Investor
0.11%
Other
87.97%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
71
871.05K
19.62%
-32.43K
2025Q2
71
462.14K
11.78%
-326.50K
2025Q1
72
466.15K
11.99%
-315.34K
2024Q4
74
6.85M
15.70%
-2.07M
2024Q3
64
6.40M
25.40%
-2.51M
2024Q2
60
6.46M
29.08%
-2.26M
2024Q1
57
6.17M
27.79%
-2.56M
2023Q4
58
6.52M
33.89%
-1.52M
2023Q3
54
8.53M
66.99%
-219.33K
2023Q2
55
8.95M
101.95%
+3.83M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Versant Ventures
162.97K
3.67%
-106.80K
-39.59%
Aug 11, 2025
The Vanguard Group, Inc.
134.61K
3.03%
+111.69K
+487.45%
Jun 30, 2025
Geode Capital Management, L.L.C.
34.74K
0.78%
+1.40K
+4.21%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
39.07K
0.88%
-3.84K
-8.95%
Jun 30, 2025
Fidelity Management & Research Company LLC
33.23K
0.75%
-1.00
-0.00%
Jun 30, 2025
UBS Financial Services, Inc.
11.22K
0.25%
-13.68K
-54.93%
Jun 30, 2025
Brady (Stephen R)
3.61K
0.08%
+46.00
+1.29%
Apr 09, 2025
Morgan Stanley Smith Barney LLC
2.11K
0.05%
+49.00
+2.38%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 07, 2025
Merger
13→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Date
Type
Ratio
Apr 07, 2025
Merger
13→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
Jun 25, 2021
Merger
15→1
FAQs
Who are the top five shareholders of Tempest Therapeutics Inc?
The top five shareholders of Tempest Therapeutics Inc are:
Versant Ventures holds 162.97K shares, accounting for 3.67% of the total shares.
The Vanguard Group, Inc. holds 134.61K shares, accounting for 3.03% of the total shares.
Geode Capital Management, L.L.C. holds 34.74K shares, accounting for 0.78% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 39.07K shares, accounting for 0.88% of the total shares.
Fidelity Management & Research Company LLC holds 33.23K shares, accounting for 0.75% of the total shares.
Versant Ventures holds 162.97K shares, accounting for 3.67% of the total shares.
The Vanguard Group, Inc. holds 134.61K shares, accounting for 3.03% of the total shares.
Geode Capital Management, L.L.C. holds 34.74K shares, accounting for 0.78% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 39.07K shares, accounting for 0.88% of the total shares.
Fidelity Management & Research Company LLC holds 33.23K shares, accounting for 0.75% of the total shares.
What are the top three shareholder types of Tempest Therapeutics Inc?
The top three shareholder types of Tempest Therapeutics Inc are:
Versant Ventures
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
Versant Ventures
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
How many institutions hold shares of Tempest Therapeutics Inc (TPST)?
As of 2025Q3, 71 institutions hold shares of Tempest Therapeutics Inc, with a combined market value of approximately 871.05K, accounting for 19.62% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 7.84%.
What is the biggest source of revenue for Tempest Therapeutics Inc?
In --, the -- business generated the highest revenue for Tempest Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
